The latest price target for Acutus Medical (OTCPK:AFIB) was reported by Goldman Sachs on August 16, 2022. The analyst firm set a price target for $1.50 expecting AFIB to rise to within 12 months (a possible 3765.98% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Acutus Medical (OTCPK:AFIB) was provided by Goldman Sachs, and Acutus Medical maintained their neutral rating.

There is no last upgrade for Acutus Medical

There is no last downgrade for Acutus Medical.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acutus Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acutus Medical was filed on August 16, 2022 so you should expect the next rating to be made available sometime around August 16, 2023.

While ratings are subjective and will change, the latest Acutus Medical (AFIB) rating was a maintained with a price target of $1.00 to $1.50. The current price Acutus Medical (AFIB) is trading at is $0.04, which is out of the analyst’s predicted range.